Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 8, 2023
- Accession no.
- 0001447362-23-000048
- Filed
- Mar 8, 2023
- Trade date
- Mar 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions. Open-market sales total $206.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2023 | Common Stock | SSaleDisposed | −2,792 | $24.71F2 | −$68,990.32 | 163,149 | Direct | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −1,396 | $24.71F2 | −$34,495.16 | 119,138 | Indirect | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −1,396 | $24.71F2 | −$34,495.16 | 108,033 | Indirect | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −697 | $24.71F2 | −$17,222.87 | 23,006 | Indirect | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −697 | $24.71F2 | −$17,222.87 | 23,007 | Indirect | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −697 | $24.71F2 | −$17,222.87 | 23,006 | Indirect | |
| Mar 6, 2023 | Common Stock | SSaleDisposed | −697 | $24.71F2 | −$17,222.87 | 22,999 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $24.380 to $25.035, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.